Table 5.
ARISTOTLE East Asia Apixaban vs Warfarin | RE‐LY Asia Dabigatran vs Warfarin | ROCKET‐AF East Asia Rivaroxaban vs Warfarin | |||||||
---|---|---|---|---|---|---|---|---|---|
Apixaban | Warfarin | HR (95% CI) | Dabigatrana | Warfarin | HR (95% CI) | Rivaroxaban | Warfarin | HR (95% CI) | |
Incidence (%/y) | Incidence (%/y) | Incidence (%/y) | Incidence (%/y) | Incidence (%/y) | Incidence (%/y) | ||||
Stroke/systemic embolism | 2.52 | 3.39 | 0.73 (0.49–1.09) | 2.50 | 3.06 | 0.82 (0.52–1.24) | 2.63 | 3.38 | 0.76 (0.42–1.37) |
All major bleeding | 2.02 | 3.84 | 0.52 (0.34–0.80) | 2.22 | 3.82 | 0.71 (0.56–0.90) | 3.44 | 5.14 | 0.63 (0.37–1.09) |
Taiwan NHIRD Cohort Apixaban vs Warfarin |
Taiwan NHIRD Cohort Dabigatran vs Warfarin |
Taiwan NHIRD Cohort Rivaroxaban vs Warfarin |
|||||||
---|---|---|---|---|---|---|---|---|---|
Apixaban | Warfarin | HR (95% CI) | Dabigatran | Warfarin | HR (95% CI) | Rivaroxaban | Warfarin | HR (95% CI) | |
Incidence (%/y) | Incidence (%/y) | Incidence (%/y) | Incidence (%/y) | Incidence (%/y) | Incidence (%/y) | ||||
Ischemic stroke/systemic embolism | 2.26 | 3.55 | 0.55 (0.43–0.69) | 2.90 | 3.55 | 0.82 (0.68–0.98) | 3.00 | 3.55 | 0.81 (0.67–0.97) |
All major bleeding | 1.52 | 3.25 | 0.41 (0.31–0.53) | 2.12 | 3.25 | 0.65 (0.53–0.80) | 1.97 | 3.25 | 0.58 (0.46–0.72) |
CI indicates confidential interval; HR, hazard ratio; and NHIRD, National Health Insurance Research Database.
Dabigatran 110 mg twice daily.